255 5-fluorouracil decreases rates of persistent actinic keratoses

Keratinocyte carcinoma (KC) is the most common cancer in the United States, with over 5 million cases treated annually. KC treatment is associated with the potential for substantial morbidity as well as significant costs, estimated at $4.8 billion per year from 2007 to 2011. Actinic keratoses (AKs) are known precursors of squamous cell carcinoma (SCC) and therefore may be a target for KC prevention. Topical 5-fluoruracil (5-FU) has been shown to...